IDEXX Laboratories (IDXX) is scheduled to report third-quarter earnings on November 3rd, with analysts anticipating EPS of $3.14 and revenue of $1.07 billion, reflecting year-over-year growth following a strong Q2 performance and raised FY25 guidance. Ahead of the release, analyst sentiment is mixed but generally positive, with Stifel upgrading the stock to Buy ($700 PT) and UBS initiating coverage with a Neutral rating ($720 PT), while other firms like Morgan Stanley, Piper Sandler, and JP Morgan maintained their ratings with updated price targets, indicating varied but mostly constructive views.
IDEXX Laboratories (IDXX) is scheduled to release its third-quarter earnings on November 3rd, with analysts anticipating robust year-over-year growth to $3.14 EPS and $1.07 billion in revenue. This follows a strong second quarter where the company exceeded expectations and subsequently raised its full-year 2025 guidance, indicating positive operational momentum. Analyst sentiment ahead of the Q3 report is largely constructive, with Stifel upgrading the stock to Buy and Morgan Stanley maintaining an Overweight rating, both accompanied by significant price target increases. While UBS and Piper Sandler hold Neutral ratings, their price targets are also notably above the current $629.51 closing price. The collective analyst actions, including multiple price target increases and an upgrade, underscore a generally optimistic outlook on IDEXX's future performance and valuation. The stock's modest 0.2% gain on Friday suggests some positive anticipation, but the upcoming earnings call will be critical in validating the raised guidance and analyst expectations.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
